Merck has received FDA approval for Capvaxive, a new vaccine designed to protect adults from pneumococcal bacteria that can cause pneumonia. Specifically targeting 21 strains of the bacteria, this vaccine is the first of its kind for adults and aims to provide broader protection than existing options. Adults with chronic health conditions are at higher risk for pneumococcal disease, which can lead to serious complications like meningitis and bacteremia. Merck's vaccine, once available, could help reduce hospitalizations and improve the quality of life for those at risk. The company is prepared to supply the vaccine by late summer pending recommendations from the CDC. With approximately 150,000 U.S. adults hospitalized for pneumococcal pneumonia annually, this new vaccine has the potential to make a significant impact on public health.